TNFRSF4 and cancer: The NPs targeted cancer cells with recognition of cluster of differentiation 44 (CD44) by HA, while co-injected anti-OX40 antibody (αOX40) reversed the immunosuppressive effect, allowing NPs to enter cancer cells favorably and release drug for chemotherapy.